The major indexes barely moved on Tuesday, but the damage under the surface was severe. A gene-therapy readout, a regulatory decision on credit scores and a Brazilian betting ban all produced steep single-stock drops on a day when the S&P 500 lost less than 0.2%. Here are the top losing stocks today, focused on the mid-caps and small caps that made the biggest headlines, not the usual mega-cap names.
Top Losing Stocks Today: Market Snapshot for Sept. 29, 2026
Stocks fell for a second straight session as Treasury yields held near multi-decade highs. The S&P 500 closed at 7,670.84. Consumer confidence dropped to its lowest level since 2014, which kept rate-hike worries alive ahead of Wednesday’s PCE inflation data and Friday’s jobs report.
| Metric | Tuesday’s Reading |
|---|---|
| Dow Jones Industrial Average | 51,349.92 (-131.59 pts, -0.26%) |
| S&P 500 | 7,670.84 (-0.16%) |
| Nasdaq Composite | 26,797.54 (-0.09%) |
| Russell 2000 | ~2,807 (-0.35%) |
| 10-Year / 30-Year Treasury Yield | 5.28% / ~5.61% (30-year at a 20-year high) |
| WTI Crude / Brent | $89.38 (-3.48%) / $102.59 |
| Gold | $4,179.70 |
| Conference Board Consumer Confidence | 81.9 vs. ~89 expected (lowest since 2014); expectations index 63.6 |
| Sector Scorecard | Financials, REITs, Consumer Discretionary and Materials are each down more than 6% in September; Tech is +4.4% |
TheStreet’s closing wrap put the theme plainly: a weakening consumer, sticky yields and a two-tier market. Small caps and rate-sensitive names took the hardest hits.
1. uniQure (QURE) | Closed $24.51, Down 37.3%
The Huntington’s Hope Trade Suffers Its Worst Day in Ten Months
uniQure collapsed roughly 37% after four-year data for its Huntington’s gene therapy AMT-130 showed a smaller benefit than the year before. It was the stock’s worst day since November 2025.
| Metric | Value |
|---|---|
| Closing Price | $24.51 |
| Prior Close | $39.11 |
| Day’s Move | -37.3% |
| 52-Week Range | $8.73 – $71.50 |
| YTD Return | ~+2% after the drop (was ~+63% at Monday’s close) |
| P/E / Dividend | N/A (pre-commercial, loss-making) / None |
| Analyst Ratings | Stifel Buy; H.C. Wainwright Buy, $80 target; Wells Fargo Overweight, $75 target; RBC Outperform |
| Balance Sheet | $259M follow-on raised this year; runway into 2030 (Q2 report) |
Catalyst: The four-year cohort of 12 high-dose patients showed 44% slowing on the composite scale. That missed statistical significance and compares with a 75% figure a year earlier.
Latest News: The company said the external-control dataset had heavy dropout, which likely understated the benefit. The 15-patient, three-year dataset behind the FDA filing still shows an 80% slowing. Five high-dose patients (17%) had serious CNS-inflammation events that later resolved.
Technicals: The stock gapped down roughly 38% within the first hour of trading and held near the lows. Momentum has flipped from euphoric to broken in a single session.
Fundamentals: No revenue and no earnings yet. The valuation rests entirely on approval odds and pricing. Leerink has estimated a U.S. price near $1.7 million if AMT-130 is approved.
Bull Case: Wells Fargo called the selloff out of proportion and argued the four-year composite is a secondary, distorted measure. RBC said the move “looks overdone.” Daily-function benefit (61% slowing at four years) held up.
Bear Case: The durability argument is now weaker. The four-year data sit outside the filed application, and FDA has reversed itself on this program twice already.
Levels to Watch Tomorrow:
- Whether shares hold above the $24.11 morning low
- Any bounce toward the $39.11 pre-drop close would signal analysts are winning the debate
- FDA acceptance of the filing, the next hard catalyst
Forecast: Expect a volatile, headline-driven tape until the FDA accepts or rejects the filing for review.
Why This Matters: This drop shows how fragile a single-asset biotech valuation is, even with bullish analysts and a strong primary dataset.
2. Fair Isaac (FICO) | Prior Close $840.89, Down Nearly 27%
The Credit-Score Monopoly Loses Its Pricing Moat
Fair Isaac cratered nearly 27%, its steepest one-day drop since May 1989, after FHFA Director Bill Pulte said Fannie Mae and Freddie Mac will move to a single pricing grid that puts VantageScore on the same footing as Classic FICO. It was the worst performer in the S&P 500.
| Metric | Value |
|---|---|
| Prior Close (Sept. 28) | $840.89 |
| Approx. Close | Near $615 (nearly -27%) |
| 52-Week High / All-Time Closing High | $1,998.01 / $2,382.40 (Nov. 2024) |
| YTD / 1-Year | Down 63%+ in 2026 (CNBC) / down ~59% |
| Market Cap | ~$18B (Motley Fool midday figure; likely a touch lower at the close) |
| Moving Averages (pre-drop) | 20-day EMA $959.54; 50-day $1,044.65; 200-day $1,215.42 |
| Fundamentals | B2B Scores revenue +49% last report, driven mainly by higher mortgage-score pricing |
| Analyst Color | RBC Outperform (flags “score shopping” risk); TD Cowen says MBS demand for FICO limits downside |
Catalyst: The single-grid move erases the roughly 20-point discount that had kept VantageScore at a disadvantage. Rocket Mortgage also said it will make VantageScore 4.0 its preferred model for eligible loans.
Latest News: TransUnion extended its $0.99 VantageScore 4.0 mortgage pricing through December 2028. FHFA has not published the unified grid or a timetable, per the Motley Fool’s coverage.
Technicals: The stock sits far below every major moving average and at its lowest levels since early 2023. It already fell about 17% on Sept. 4, so this is the second leg of a regulatory-driven breakdown.
Fundamentals: FICO’s profit engine is mortgage-origination score pricing. That is exactly what the FHFA is targeting.
Bull Case: Lenders and mortgage-backed-securities buyers may still want a FICO score on every loan, preserving volume even as pricing competition grows.
Bear Case: If lenders shift production loans to VantageScore, FICO faces both share loss and forced price cuts. The stock has lost more than half its value in 2026.
Levels to Watch Tomorrow:
- Whether shares hold near the $615 close or slip below the $600 round number
- The $840.89 pre-drop close, the gap any rebound would have to fill
Forecast: Volatility stays extreme until FHFA publishes the unified grid and an effective date.
Why This Matters: A pricing-power franchise lost a quarter of its value in one session because of a single social-media post. Regulatory moats are only as strong as the regulator’s patience.
3. DraftKings (DKNG) | Closed $19.59, Down 7.4%
Sportsbook Contagion Pushes DKNG to a Fresh 52-Week Low
DraftKings slid 7.4% to close near $19.59, a new 52-week low and its lowest level since early 2023.
| Metric | Value |
|---|---|
| Closing Price | $19.59 |
| Prior Close | $21.16 |
| Day’s Move | -7.4% |
| 52-Week Range | Low now $19.59 (prior floor ~$19.74) / high ~$41.94 |
| 1-Month Move | ~-18% (from ~$24 on Sept. 4) |
| Revenue / Margin | ~$6.05B trailing revenue; ~40.5% gross margin; still unprofitable |
| P/E / Dividend / Beta | N/M (negative earnings) / None / ~1.63 |
| Moving Averages | ~10.6% below 20-day SMA (~$23.00); ~20.8% below 200-day SMA (~$25.97); “death cross” since Oct. 2025 |
| Analyst Consensus | “Moderate Buy,” average target ~$34.29; Citizens $35 |
Catalyst: Brazil’s ban on online betting, which forced Flutter to halt operations there, hit the whole sector even though DraftKings has no Brazilian exposure. An expanding congressional probe into prediction markets added pressure.
Latest News: Reuters reported Kalshi is in advanced talks to raise $1 billion at a $40 billion valuation, a reminder of the competition from prediction markets. A federal appeals court ruled that sports bets are not swaps, a modest positive.
Technicals: Every rebound since August has been weaker than the last. MACD sits below its signal line, meaning bounces keep failing.
Fundamentals: Growth is real, but the market is pricing sportsbook margins and event-contract spending, not the prediction-market upside.
Bull Case: Analyst targets sit roughly 70% above the stock, and football-season hold rates could normalize.
Bear Case: Regulatory risk, state tax hikes and prediction-market competition are all rising at once. The stock has no earnings cushion.
Levels to Watch Tomorrow:
- A reclaim of the $20.50 area (the former floor)
- Monday’s $21.16 close as the first real recovery marker
- A further break below $19.59 would extend the slide
Forecast: Sentiment-driven and headline-sensitive into the next earnings report.
Why This Matters: DraftKings fell harder than the company that actually got banned, a sign of how crowded and fragile the online-betting trade has become.
4. Neogen (NEOG) | Roughly $12.97, Down 5.5%
A Horse-Deaths Warning Letter Hits a Stock That Had Doubled
Neogen fell about 5.5% after the FDA disclosed warning letters tied to a contaminated “sterile” veterinary wound product linked to nearly 100 sick horses.
| Metric | Value |
|---|---|
| Latest Quote | ~$12.97 (-5.47%) |
| Prior Close | ~$13.72 |
| 1-Year Move | ~+113% (as of early Sept.) |
| Market Cap | ~$2.8B (about 218M shares) |
| P/E / Dividend | N/M (small net loss) / None |
| Fiscal 2026 | Revenue $870.4M (-2.7%); net loss $7.9M; Q4 revenue $225.3M, net loss $11.3M |
| Guidance | Fiscal Q1 2027 revenue of $207M–$209M |
| Analyst View | “Buy” consensus; targets recently raised to ~$14 |
| Beta | ~1.8 |
Catalyst: FDA testing found fungal contamination in the product. At least 20 horses were euthanized, the most deaths ever tied to a quality defect in an FDA-regulated veterinary product.
Latest News: The Sept. 23 warning letter says Neogen is responsible for its contract manufacturer’s quality. The company has 15 working days to submit a corrective-action plan. Separately, Australia is running a Phase 2 review of Zoetis’ $160 million purchase of Neogen’s genomics unit.
Technicals: Shares are pulling back after a run that more than doubled the stock, and are volatile with a beta near 1.8.
Fundamentals: The business is turning around slowly, but a large share of the stock’s move this year rested on that transformation story.
Bull Case: The recalled lots date to January, so the financial exposure may be contained, and the transformation plan is intact.
Bear Case: Regulators have flagged quality-oversight failures, which can bring litigation, added compliance cost and reputational drag.
Levels to Watch Tomorrow:
- Whether $12.97 holds
- The $13.72 prior close as the first recovery marker
- Any Neogen response to the FDA
Forecast: The stock should trade on regulatory and litigation headlines until the corrective-action response is public.
Why This Matters: A single contract-manufacturing lapse can erase months of turnaround progress.
5. TransUnion (TRU) | Down 4.6% on the Day
The Credit Bureau Caught in Its Own VantageScore Crossfire
TransUnion fell 4.6% even as its own pricing move helped trigger FICO’s collapse. Its Tuesday closing price was not published in our sources.
| Metric | Value |
|---|---|
| Day’s Move | -4.6% |
| Last Verified Price | $71.88 (Sept. 22–23 print) |
| Market Cap | ~$13.9B at that price |
| Dividend | $0.125 quarterly (~0.7% yield) |
| Latest Quarter (Q2) | EPS $1.18 vs. $1.11 expected; revenue $1.25B |
| Adoption Data | VantageScore 4.0 used by 1,100+ mortgage lenders, including 9 of TransUnion’s 15 largest |
| Analyst View (as of July) | “Moderate Buy,” average target ~$91.60 |
| 2026 Low | ~$65.24 (spring) |
Catalyst: Investors sold the sector after FHFA’s announcement. TransUnion, Equifax and Experian co-own VantageScore, but they also earn money distributing FICO scores.
Latest News: TransUnion is holding VantageScore 4.0 at $0.99 per standalone mortgage score through 2028 and giving it away to customers who buy a FICO score.
Technicals: The stock was already in a downtrend, having fallen about 9% on Sept. 4.
Fundamentals: Earnings beat last quarter, but a lower-priced score could compress mortgage-scoring revenue per unit.
Bull Case: Share gains for VantageScore could be a net positive, and the market may be lumping TransUnion in with FICO unfairly.
Bear Case: Cheaper scoring cannibalizes revenue, and regulatory intervention is unpredictable.
Levels to Watch Tomorrow:
- The $71.88 reference price
- The spring low near $65.24, which would be the next major test if selling continues
Forecast: TransUnion will trade in sympathy with FICO and mortgage-policy headlines.
Why This Matters: Even the beneficiary of a policy shift got sold, showing how indiscriminate sector selling can be.
6. XPeng (XPEV) | Near $9.54, Down 4.1%
A JPMorgan Downgrade Slashes the Target by More Than Half
XPeng shares fell 4.1% to a new 52-week low after JPMorgan cut the stock to Neutral from Overweight.
| Metric | Value |
|---|---|
| Latest Quote | ~$9.54 (session low ~$9.47) |
| Prior Close | $9.95 |
| Day’s Move | ~-4.1% |
| RSI | 26.3 (oversold) |
| Moving Averages | ~9.5% below 20-day SMA (~$10.51); ~17% below 50-day (~$11.48); ~39% below 200-day (~$15.68) |
| Analyst Moves | JPMorgan to Neutral, target to $11.50 from $24; UBS Neutral, $12; Barclays Underweight, $14 |
| Rating Split | 1 Strong Buy, 4 Buy, 2 Hold, 4 Sell (MarketBeat count) |
| August Deliveries | 39,107 vehicles |
Catalyst: JPMorgan cited structural challenges in the auto sector.
Latest News: The decline looks stock-specific and follows weak delivery guidance and skepticism about the company’s robot unit. Short-borrow conditions are reportedly tight.
Technicals: An RSI in the mid-20s signals oversold conditions, but the trend is firmly down and every rally has stalled below $11.
Fundamentals: Delivery momentum is the key metric, and the market is questioning both volume and margins.
Bull Case: Oversold readings and a tight borrow can fuel sharp short-covering bounces. Some analysts still hold Buy ratings.
Bear Case: Four Sell ratings, a slashed JPMorgan target and a broken trend make catching the bottom risky.
Levels to Watch Tomorrow:
- The $9.47 session low
- A rebound toward $11 would be the first technical relief
Forecast: Expect continued pressure unless October delivery numbers surprise.
Why This Matters: A halved price target from a major bank can reset expectations for an entire Chinese-EV ADR.
7. Westlake (WLK) | Near $64.55, Down About 3.4%–4%
A German PVC Plant Closure Comes With a $205 Million Bill
Westlake announced it will close its Cologne PVC plant and warned that third-quarter performance will weaken sequentially. Shares fell as low as $64.55 in the morning; reports put the session decline near 4%.
| Metric | Value |
|---|---|
| Morning Print | $64.55 (-3.4%) |
| Implied Prior Close | ~$66.80 |
| Closure Charges | ~$205M pre-tax (~$100M cash, ~$105M non-cash); ~$110M booked in 2026 |
| Plant Capacity | ~165,000 metric tons of PVC per year |
| Dividend | $0.533 quarterly (~3.3% yield at ~$64.55, calculated) |
| P/E | N/M (negative earnings) |
| Insider Activity | Executive Chairman Albert Chao sold 38,873 shares (~$3.1M) in the past six months |
| Analyst View | Mixed guru ownership; valuation screens undervalued but fundamentals weak |
Catalyst: Westlake cited weak demand, high energy costs and competition from Asian imports.
Latest News: The plant will cease operations in Q1 2027. North American PVC and polyethylene prices fell in Q3 versus Q2, and higher freight costs hurt the Housing & Infrastructure Products segment.
Technicals: A gap-down on a large one-time charge in a stock already under pressure from a soft chemicals cycle.
Fundamentals: The closure should improve European profitability over time, but near-term earnings are negative.
Bull Case: Shuttering a high-cost plant is disciplined, and the dividend yield offers some support.
Bear Case: Demand is soft on both sides of the Atlantic, and the guidance warning suggests more pain ahead.
Levels to Watch Tomorrow:
- The $64.55 morning low
- The implied ~$66.80 pre-news close
Forecast: Expect range-bound trading until the Q3 report quantifies the hit.
Why This Matters: Even large chemical producers are being forced to shut capacity in Europe as energy costs and imports squeeze margins.
8. Flutter Entertainment (FLUT) | Low of $74.39, Lowest Since March 2020
The World’s Biggest Sportsbook Loses a Country and Its Footing
Flutter fell another ~3% at its Tuesday low to $74.39, valuing the business near $12.9 billion. That is its weakest level since March 2020. Its official Tuesday close was not published in our sources.
| Metric | Value |
|---|---|
| Tuesday Low | $74.39 (about -3% intraday) |
| Monday Close | $76.63 (-7.5% to -7.9% depending on source) |
| Market Cap | ~$12.9B at the low |
| From Aug. 2025 Peak | ~-76% (52-week high ~$308.60) |
| Latest Annual Financials | Revenue ~$16.4B; net loss ~$310M |
| Analyst View | Average target ~$143.6 (range $91–$360) |
| Technicals | MACD -3.8 (sell signal) |
| Short Interest | ~5.2% net short disclosed (July data) |
Catalyst: Brazil’s provisional ban on online betting, effective Sept. 25, forced Flutter to stop operating there.
Latest News: The company estimates a hit of roughly $70 million to 2026 revenue and $20 million to adjusted EBITDA. India’s earlier ban had already cost about $250 million in expected 2026 revenue. Jefferies flagged unusually low hold in New York.
Technicals: Trading at multi-year lows with a bearish MACD.
Fundamentals: Brazil is a small slice of group revenue. The larger worry is the pattern of regulatory shocks and slower prediction-market execution.
Bull Case: Regulus Partners expects the Brazil ban to be overturned eventually. The Street’s average target is roughly double the stock price.
Bear Case: Two international bans, guidance cuts and sportsbook hold volatility suggest more downside risk.
Levels to Watch Tomorrow:
- The $74.39 low
- The $76.63 Monday close as the first recovery marker
Forecast: Trading will follow Brazilian court and congressional headlines.
Why This Matters: Flutter has now fallen roughly 76% from its 2025 peak, showing that market leadership offers little shelter from regulatory risk.
9. Equifax (EFX) | Down 2.65%, Near 12-Month Lows
Goldman Cuts Its Target as the Credit-Score Selloff Spreads
Equifax fell 2.65% after Goldman Sachs cut its target to $171 from $199 and kept a Neutral rating. Tuesday’s closing price was not published in our sources.
| Metric | Value |
|---|---|
| Day’s Move | -2.65% |
| Last Verified Price | ~$150.31 (Sept. 24, a new 52-week low print) |
| Market Cap / P/E | ~$17.4B / ~26.1 (at that price) |
| Dividend | $0.56 quarterly ($2.24 annualized, ~1.5% yield) |
| Moving Averages (as of Sept. 24) | 50-day ~$176.73; 200-day ~$174.01 |
| Latest Quarter | EPS $2.25 vs. $2.20 expected; revenue $1.70B (+10.6%) |
| 2026 Guidance | EPS $8.39–$8.69 |
| Analyst View | 15 Buy / 6 Hold; pre-cut average target ~$214.53; Wells Fargo $200; Goldman $171 |
Catalyst: Goldman’s target cut and the FICO-driven credit-bureau selloff.
Latest News: Equifax hit a new 52-week low on Sept. 24, and CEO Mark Begor sold 37,791 shares in July under a pre-arranged plan.
Technicals: The stock trades well below both its 50-day and 200-day averages and is down roughly 41% over the past year.
Fundamentals: Earnings are growing, but the market is worried about scoring-price competition and mortgage-volume sensitivity.
Bull Case: Fifteen analysts rate it Buy, and earnings and revenue are still growing at a healthy rate.
Bear Case: The stock trades near lows, momentum is negative, and even the Neutral-rated Goldman is cutting targets.
Levels to Watch Tomorrow:
- The ~$150 area, last year’s low print
- Goldman’s $171 target as an upside reference
Forecast: Equifax should track credit-bureau sentiment until FHFA publishes its unified grid.
Why This Matters: Equifax shows how one regulator’s decision can lower the entire credit-data sector’s valuation multiple.
10. MongoDB (MDB) | Monday Close $334.68 (-18.5%), Still Sliding Tuesday
A Surprise CEO Exit Keeps Bleeding Into Investor Day
MongoDB extended its slide on Tuesday after Monday’s 18.5% plunge when CEO CJ Desai left for Meta after less than a year. Tuesday’s official close was not confirmed in our sources.
| Metric | Value |
|---|---|
| Monday Close | ~$334.68 (-18.46%); Friday close $410.44 |
| Monday Low | $300 |
| 52-Week Range | $215.68 – $473.10 |
| YTD / 1-Month | ~-20% / ~-25% |
| Valuation | Trailing P/E ~466x; ~6.5x projected 2028 revenue (Stifel) |
| Guidance | Q3 revenue $756M–$761M; Atlas growth ~27% |
| Analyst View | Buy consensus; averages ~$457–$479; Citi high at $565 |
| Dividend | None |
Catalyst: Desai’s exit to lead Meta’s new enterprise unit is MongoDB’s second CEO change in under 12 months.
Latest News: Former CEO Dev Ittycheria is interim CEO, and guidance was reaffirmed. MongoDB launched version 9.0 and “Atlas Infinite” on Tuesday, the same day as its investor day.
Technicals: Monday’s low of exactly $300 was a psychological level, and buyers stepped in there. Tuesday saw weakness again.
Fundamentals: Operations look steady, but investors want a permanent leader and proof the AI-era strategy survives the transition.
Bull Case: Analysts see roughly 40% or more upside to their targets. Ittycheria grew revenue from about $35 million to over $2.3 billion.
Bear Case: Leadership churn, a costly valuation and an unfinished CEO search can keep buyers cautious.
Levels to Watch Tomorrow:
- The $300 low from Monday
- The $334.68 Monday close
- The $410.44 pre-announcement price
Forecast: The CEO search and investor-day takeaways will drive sentiment.
Why This Matters: MongoDB lost more than $6 billion in market value in a single day because of one executive’s decision, a lesson in key-person risk.
Sector Sentiment Snapshot: What Today’s Top Losing Stocks Reveal
Three themes dominated the stocks down today:
- Regulatory shocks: FICO, TransUnion and Equifax fell on one FHFA decision. Flutter and DraftKings fell on Brazil’s betting ban. Neogen fell on an FDA warning letter.
- Binary biotech risk: uniQure showed how quickly a single readout can erase a year of gains.
- Macro pressure: With the 30-year yield near a 20-year high and consumer confidence at a 12-year low, rate-sensitive and growth names are struggling. Small-cap microcaps suffered too; for that corner of the market, see our penny-stock watchlists.
Forecast: Wednesday’s PCE inflation data and Friday’s jobs report are the next macro tests. A hot print would extend pressure on yield-sensitive names, and a cool one could spark relief bounces in oversold stocks like XPeng and DraftKings. As earnings season nears, expect more guidance-driven single-stock moves like the ones in our earnings-season breakdown.
At a Glance: Today’s Top Losing Stocks
| # | Ticker | Price Reference | Day’s Move | Key Catalyst |
|---|---|---|---|---|
| 1 | QURE | $24.51 close | -37.3% | Weaker four-year Huntington’s data |
| 2 | FICO | ~$615 (prior close $840.89) | ~-27% | FHFA single pricing grid |
| 3 | DKNG | $19.59 close | -7.4% | Brazil-ban sympathy; new 52-week low |
| 4 | NEOG | ~$12.97 | -5.5% | FDA warning letter on contaminated product |
| 5 | TRU | Last verified $71.88 (Sept. 22–23) | -4.6% | Credit-score sector selloff |
| 6 | XPEV | ~$9.54 | ~-4.1% | JPMorgan downgrade; target cut to $11.50 |
| 7 | WLK | ~$64.55 (morning) | ~-3.4% to -4% | Cologne plant closure; $205M charge |
| 8 | FLUT | $74.39 low | ~-3% intraday | Brazil ban; lowest since March 2020 |
| 9 | EFX | ~$150 (Sept. 24 print) | -2.65% | Goldman target cut to $171 |
| 10 | MDB | $334.68 (Monday close) | Monday -18.5%; lower Tuesday | CEO exit to Meta |
Follow TNN for daily stock market news and financial news today.
Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss, and clinical-stage biotech and small-cap stocks carry elevated risk. Stock prices, percentage moves, and market data cited reflect figures available at the time of publication and are subject to change. Some prices in this article are approximate or reflect the most recent verified print, as exact closing figures for certain names were not available at the time of writing. Analyst price targets and ratings are third-party estimates and do not guarantee actual results. Always complete independent due diligence prior to executing equity trades.
About The Author
